Methods for treating or preventing ophthalmological conditions
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.
1. A method of treating geographic atrophy in a human subject in need thereof, the method comprising administering via intravitreal injection to said subject about 2 mg/eye of a pegylated aptamer in an amount sufficient to reduce growth of a lesion associated with geographic atrophy in the subject, wherein the aptamer comprises the sequence
fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGf UfCfUmGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO:26),
wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof, and
wherein the pegylated aptamer is administered to the subject biweekly, monthly, or quarterly.
2. The method according to claim 1 , wherein the pegylated aptamer is provided as a pegylated moiety conjugated to the aptamer via a linker.
3. The method according to claim 2 , wherein the pegylated moiety is conjugated to the 5′ end of the aptamer.
4. The method according to claim 2 , wherein the pegylated moiety is a branched PEG.
5. The method according to claim 2 , wherein the pegylated moiety has a molecular weight greater than about 10 kDA.
6. The method according to claim 2 , wherein the pegylated moiety has a molecular weight of about 40 kDa.
7. The method according to claim 1 , wherein the pegylated moiety has the following structure:
8. The method according to claim 1 , wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 10%, as compared to a subject who is not administered the anti-C5 agent.
9. The method according to claim 1 , wherein the anti-C5 agent is administered monthly.
10. The method according to claim 9 , wherein the anti-C5 agent is administered monthly for three injections, and the fourth and fifth injections are administered three or four months after the third injection.
11. The method according to claim 1 , wherein the anti-C5 agent is administered bimonthly.
12. The method according to claim 1 , wherein the anti-C5 agent is administered quarterly.
13. The method according to claim 1 , wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 20% as compared to a subject who is not administered the anti-C5 agent.
14. The method according to claim 1 , wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 30% as compared to a subject who is not administered the anti-C5 agent.
15. The method according to claim 1 , wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 40% as compared to a subject who is not administered the anti-C5 agent.
16. The method according to claim 1 , wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 50% as compared to a subject who is not administered the anti-C5 agent.
17. The method according to claim 1 , wherein growth of the lesion is assessed using autofluorescence imaging or optical coherence tomography.
18. A method of treating geographic atrophy in a human subject in need thereof, the method comprising administering via intravitreal injection to said subject about 2 mg/eye of a pegylated aptamer in an amount sufficient to reduce growth of a lesion associated with geographic atrophy in the subject, wherein the aptamer comprises the sequence
fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGf UfCfUmGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO:26),
wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof, and
wherein the pegylated aptamer is administered to the subject biweekly, monthly, or quarterly,
wherein the pegylated moiety is a branched PEG and has a molecular weight greater than about 10 kDA, and
wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 30% as compared to a subject who is not administered the anti-C5 agent.
19. A method of treating geographic atrophy in a human subject in need thereof, the method comprising administering via intravitreal injection to said subject about 2 mg/eye of a pegylated aptamer in an amount sufficient to reduce growth of a lesion associated with geographic atrophy in the subject, wherein the aptamer comprises the sequence
fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGf UfCfUmGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO:26),
wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof, and
wherein the pegylated aptamer is administered to the subject biweekly, monthly, or quarterly,
wherein the pegylated moiety is a branched PEG and has a molecular weight greater than about 10 kDA, and
wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 40% as compared to a subject who is not administered the anti-C5 agent.